Advertisement

We need your help now

Support from readers like you keeps The Journal open.

You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.

If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.

Sasko Lazarov/Photocall Ireland
Cystic Fibrosis

Cystic fibrosis patients begin move to new €22m unit

The new specialised facility at Dublin’s St Vincent’s Hospital comes after an eight-year campaign to provide those suffering with the condition with better care.

CYSTIC FIBROSIS PATIENTS are beginning to be transferred from St Vincent’s Hospital to the new €22 million Nutley Wing.

The move to the new specialised facility comes after an eight-year campaign to provide those suffering with the condition with better care.

The new wing is expected to be opened fully over August, with a minimum of 20 beds and 34 inpatients opening, reports RTÉ.

The new single rooms reduce the risk of cross-infection for vulnerable cystic fibrosis patients.

Last week, the European Medicines Agency approved a new drug which can help people with a certain form of cystic fibrosis. Kalydeco, manufactured by Vertex, which treats people with cystic fibrosis aged six and over who have at least one copy of the G551d mutation.

An estimated 1,100 people in Europe have the G551D mutation, with about 100 of those living in Ireland.

Regulators in Ireland must now approve the drug ahead of any negotiations between Vertex and the HSE corporate pharmaceutical unit regarding pricing for the drug, which has now approved in both Europe and the United States.

Read: New drug for cystic fibrosis approved by European regulators>

Your Voice
Readers Comments
11
    Submit a report
    Please help us understand how this comment violates our community guidelines.
    Thank you for the feedback
    Your feedback has been sent to our team for review.